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Abstract: This review provides an overview of the known effects of diet, obesity, and the intake of
different nutrients on systemic lupus erythematosus (SLE). It summarizes and discusses the studies
in rodents that identified how different diets can regulate gene expression in the disease, together
with a description of the effects of diet on lupus patients’ inflammatory state and disease severity.
The identification of selected dietary candidates that can modulate SLE onset and progression is
analyzed in relation to possible targeted approaches that could ultimately ameliorate the management
and prognosis of this disease.
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1. Introduction
Systemic lupus erythematosus (SLE) is a systemic autoimmune disease characterized by immune
responses to multiple self-antigens, mostly of intracellular origin and including cell nucleus and DNA
molecules. The dysregulation of innate and adaptive immune responses in SLE is secondary to several
abnormalities that include an impaired clearance of apoptotic cells and an increased availability of
self-antigens that induce production of autoantibodies that can form immune complexes with their
cognate antigen, fix complement, and deposit in tissue where they can cause damage and impaired
organ function [1].
Genetics alone is not sufficient to explain the development of SLE, and environmental triggers
influence the development and expression of the disease. Among the environmental factors that
modulate the onset and progression of SLE, diet plays a critical role. Nutrients not only impact overall
health but also alter the gut microbiota composition and the immune response. In other words, the
host’s metabolic status, which highly depends on diet, can favor or not the development of immune
abnormalities manifesting with varied symptoms and/or organ involvement that depend on the genetic
backgrounds and additional factors [2]. This explains why patients with SLE often benefit from
individualized dietary changes tailored according to their condition, in addition to general approaches
of weight loss when obese.
2. Diet and Gene Expression in SLE
2.1. PUFA
Both lupus-prone mice and patients with SLE benefit from a dietary consumption of n-3
polyunsaturated fatty acids (n-3 PUFA). Mammals, including humans, are not able to synthesize PUFA
and thus require those nutrients from exogenous sources such as fish oil [3]. PUFA are found in dietary
oils from plants such as corn and soybean, where linoleic acid is most represented [4].
The beneficial effects of dietary n-3 PUFA have been associated with anti-inflammatory activities
induced by the suppression of proinflammatory cytokine production and the promotion of antioxidant
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enzyme activities, in addition to a reduced immune effector activity and a decreased antigen
presentation [5].
Clinical trials have provided evidence that the consumption of fish oil benefits lupus patients [6,7].
Those trials followed encouraging studies in mice that had indicated that a diet that included fish
oil provided beneficial effects in multiple strains of lupus-prone animals. In addition to delaying
lupus disease manifestations, fish oil reduced the expression of IL-1β, TNF-α, and ICAM-1 in (NZB
x NZW)F1 (BW) mice, while it increased the expression of antioxidant enzymes [8,9]. Reduced
lupus disease manifestations were seen, as well, in BXSB/MpJ and MRL-lpr lupus-prone mice [10],
together with a reduced expression of the proinflammatory cytokines IL-6, IL-12, and TNF-α [11].
Further comparisons among different dietary lipids confirmed the beneficial effects of fish oil on
lupus manifestations in BW mice. In those experiments, one group of BW mice received a diet rich in
PUFA with docosahexaenoic acid-enriched fish oil (DFO). A second group received n-6 PUFA-rich
western-type diet, containing corn oil (CRN), and the third group received n-9 monounsaturated
fatty acid (MUFA)-rich Mediterranean-type diet containing high oleic safflower oil (HOS). Mice fed
n-6 PUFA or n-9 MUFA developed clinical manifestations of SLE including autoantibodies and renal
disease, while mice fed n-3 PUFA diet did not develop similar signs [3] (yet other studies had found
protective effects deriving from n-6 PUFA [12]). Gene expression analyses on sorted CD4+ T cells, the
helper cells in the production of autoantibodies from B cells, provided a comparison, by PCR array,
of the relative expression of 84 genes in kidneys and spleens from the three different groups of mice.
At week 34, 33 genes were downregulated and 3 upregulated in kidneys of DFO-fed mice as compared
to HOS-fed mice, and 37 were downregulated and 2 upregulated as compared to CRN-fed mice.
In the spleens, 26 genes were downregulated and 1 was upregulated in DFO-fed mice as compared
to HOS-fed mice, and 25 genes were downregulated and 7 upregulated as compared to CRN-fed
mice [3]. The genes whose expression was modulated by DFO associated with inflammatory responses,
T and B cell activation/differentiation, leukocyte recruitment, and antigen presentation. Quantitative
RT-PCR of representative genes showed that dietary n-3 PUFA associated with a reduced expression of
multiple genes involved in proinflammatory responses leading to a reduced expression of IL-6, IL-18
and TNF-α, and reduced expression of CCL-5 chemokine and CXCR3 chemokine receptor, osteopontin,
and the costimulatory molecules CD80 and CTLA-4 [3].
2.2. Polyphenols
The phenolic fraction of extra virgin olive oil has anti-inflammatory and immunomodulatory
properties that associated with a reduced production of pro-inflammatory TNF-α, IL-6, IL-1β, and
IFN-γ in 38 lupus patients’ peripheral blood mononuclear cells (PBMCs) [13]. In addition to a reduced
T cell (CD69+) activation, the phenolic fraction of extra virgin olive oil increased the expression of IκBα
due to the prevention of its degradation, leading to downregulation of NFκB (IκBα inhibits NFκB),
together with the inhibition of ERK1/2 phosphorylation [13].
2.3. Sodium Chloride (NaCl)/Salt Intake
Other studies found that high salt intake in the diet of lupus-prone MRL/lpr mice led to an
increased frequency of proinflammatory Th17 and Th1 cells that associated with an increased disease
severity and shortened lifespan [14]. Interestingly, the promoting proinflammatory effects of high
salt treatment could be reversed in vitro on lupus patients’ Th17 cells co-cultured with serum and
glucocorticoid-inducible serine/threonine protein kinase 1 (SGK1), which governs cellular Na+ transport
and NaCl homeostasis [14].
The deleterious effects of high salt in MRL/lpr mice on the acceleration and worsening of lupus
disease manifestations associated with high salt-induced promotion of T follicular helper (Tfh) cell
differentiation [15]. Tfh cells have a critical role in the pathogenesis of SLE since they regulate
the selection and survival of B cells in the germinal centers, thus contributing to the regulation of
autoantibody production in the disease. NaCl-treated CD4+ T cells had DNA hypomethylation and
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increased DNA hydroxymethylation that correlated with higher levels of the hydroxyltransferases
ten-eleven translocation (TET)3 and TET2, the latter playing an important role in Tfh cell differentiation
(and NaCl-induced Tfh cell promotion via regulation of Spn gene expression). In addition to SPN,
NaCl increased the expression of SH2D1A, MAP3K1, and STAT5B in SLE patients as compared with
controls [15]. By enhancing the expression of MAP3K1 and SPN and by inducing DNA hypomethylation
of genes involved in immune responses, NaCl operated at different levels in inducing Tfh cells. During
Tfh differentiation, the expression of SPN and STAT5B was upregulated, even more by NaCl, indicating
an influence of NaCl on genes involved in Tfh differentiation. Moreover, ChIP-qPCR was performed to
further explore the interaction between TET2 and NaCl-increased genes expression. There was TET2
enrichment on Spn and Stat5b, indicating that increased expression of SPN and STAT5B might associate
with enrichment of TET2 after NaCl addition. Gene silencing confirmed that regulation of Tfh cell
differentiation by Spn was a target of NaCl [15]. Maps of gene expression and DNA methylation of
NaCl-treated human CD4+ T cells showed that NaCl induced DNA hypomethylation of genes involved
in cell differentiation and development (DNA hypomethylation facilitates gene transcription). High
salt-treated cells displayed decreased the expression of BLIMP (which promotes Th17, Th1, and Th2
cells) and Th1 (IFN-γ) and Th2 (IL-4 and IL-10) cytokines. The genes that were increased were instead
involved in T cell differentiation and activation (Icos, Pdcd1, Stat1, and Sh2d1a), including the master
regulator of the germinal center reaction Bcl-6.
Together, these studies show that high-salt diet could provide an epigenetic contribution to the
pathogenesis of SLE.
2.4. Vitamins
Dietary supplementation with selected vitamins can have beneficial effects in SLE [16]. Low levels
of vitamin D that are common in lupus patients, secondary to the avoidance to sun exposure and/or
a reduced dietary intake, have been associated with an increased disease activity. Beneficial effects
deriving from vitamin D supplementation in SLE associate with increased numbers of T regulatory
cells (Tregs) [17] and the inhibition of the formation of neutrophil extracellular trap (NET)s that cause
endothelial damage [18].
Additionally, the administration of the active metabolite of vitamin A, the all-trans-retinoic acid
(tRA), also ameliorates SLE in both patients and mice [19–21].
2.5. Amino Acids and mTOR
A limited consumption of phenylalanine and tyrosine in lupus-prone mice or a moderate protein
intake is useful in improving renal function in SLE patients [22]. Accumulation of the tryptophan
metabolite kynurenine or the depletion of cysteine and glutathione in SLE promote the activation of
the mTOR kinase that fuels inflammation [23,24]. Treatment of lupus patients with the mTOR blockers
acetylcysteine [25] or rapamycin [26] provides significant beneficial therapeutic effects that envision
potential additional approaches of mTOR blockade (e.g., through calorie restriction [27]) for a possible
reduction of the chronic inflammatory state in SLE patients.
3. Epigenetic Effects of Diet on SLE
Epigenetics is the branch of biology that studies the stable, reversible, and heritable changes in gene
expression resulting from DNA or chromatin modification or post-transcriptional mechanisms that do
not associated with changes in DNA coding sequences [28]. These changes include DNA methylation,
histone modifications, non-coding RNA expression—i.e. microRNA (miRNA)s, chromatin remodeling,
and gene imprinting. Failure to maintain epigenetic homeostasis, e.g. due to environmental causes
that can include diet, may result in altered activities at the levels of the cell nucleus, transcriptome, or
gene expression.
Diet is a key environmental component that influences host’s gene expression. Altered DNA
methylation pattern and subsequent changes in gene expression have been observed in embryos from
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pregnant mice fed diets that were rich in methyl donors [29]. Dietary supplementation with methyl
donors increased DNA methylation in leucocytes [30] whereas a limited dietary intake of methyl donors
associated with DNA hypomethylation [31]. This led to the suggestion that diets rich in methyl group
donors and essential fatty acids could have beneficial effects on SLE. Metabolomic analyses found
that the reduction in energy biogenesis in the disease significantly decreased glycolysis, Krebs cycle,
fatty acid β-oxidation, and amino acid metabolism associated with deficiencies of many anti-oxidants
including glutathione and methyl group donors [32]. It also elevated markers of oxidative stress
from lipid peroxidation products including malondialdehyde, γ-glutamyl peptides and γ-glutamyl
transaminase, leukotriene B4, and 5-hydroxyeicosatetraenoic acid [32]. These findings suggested
the possibility that these abnormalities could be corrected by dietary intervention [32], and dietary
micronutrients necessary for transmethylation were tested in mice to see whether they could influence
SLE (lupus patients have a deficiency of methylation-associated micronutrients) [32]. Transmethylation
micronutrient–restricted (MR) and transmethylation micronutrient–supplemented (MS) diets were
evaluated on the expression of methylation-sensitive T cell genes and lupus disease as mice fed on a
low-methionine formulation or a diet rich in methyl donors and cofactorszinc, folic acid, and vitamin
B12 [33]. The study found that the diet with reduced methionine content increased lupus disease
severity, whereas the diet enriched in methyl donors and cofactors reduced anti-DNA antibody levels
and renal disease [33]. Thus, SLE is modulated by DNA methylation that is influenced by the diet, and
the interaction of genes and dietary micronutrients can affect murine lupus disease activity and severity.
In addition to methylation, other epigenetic components under investigation in SLE that are
influenced by diet are the miRNAs (discussed elsewhere) [34].
4. Diet and Microbiome in SLE
Diets can also influence the host’s gut microbiome, imparting changes in the flora composition
that have been associated to the pathogenesis of autoimmune diseases [35]. In SLE, the intake of
polyphenols influences the composition of the fecal microbiota, and foods rich in flavonoids contribute
to an increase in fecal levels of beneficial microorganisms (Lactobacillus and Bifidobacterium) in lupus
patients [36]. On the other hand, interactions between the microbiome and innate and adaptive
immune cells can influence immune responses at many levels that include commensal-mediated
post-translational modification of self-antigens or the cross-reactivity between commensal and host
antigens [37].
5. Caloric Intake, Obesity and Gene Expression in SLE
Diets directly influence body weight. Food restriction and/or calorie restriction have long been
known to be beneficial in reducing disease manifestations in lupus-prone mice [38,39], including a
lowered atherogenic risk, through mechanisms that include a reduced expression of IL-12 and IFN-γ,
reduced NF-κB activation [38,40], and the induction of immunosuppressive CD4+ Tregs [39].
Although the therapeutic management of SLE that frequently includes the use of corticosteroids
affects the patient’s body mass significantly, an excess weight in lupus patients is problematic not
only because of its association with impaired functional capacity and fatigue but also because of its
implication in worsening the patient’s clinical picture and increased generalized inflammation.
Measurements of the body mass index of lupus patients indicated that about 35% of SLE patients
are overweight and about 27% are obese [41]. Another study found that 28% of lupus patients are
overweight and 39% are obese, and carriers of higher concentrations of inflammatory markers including
C-reactive protein (CRP) [42].
Obese lupus patients have increased gene and protein expression of several proinflammatory
molecules such as the cytokines IL-23 [43] and TNF-α, the latter being associated with total fat mass
on the trunk region in pediatric lupus patients [44]. This state of inflammation that is associated
with obesity creates a background with an increased likelihood to develop complications such as
the metabolic syndrome (increased blood pressure, high blood glucose levels, and dyslipidemia).
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Therefore, obese lupus patients have a high prevalence of metabolic syndrome that directly contributes
to the worsening of their chronic inflammatory status because to increased oxidative stress. Together
with serum uric acid, increased in the metabolic syndrome, secondary inflammation in obese lupus
patients sustains a vicious cycle of oxidative stress through increased CRP gene expression and elevated
protein oxidation and lipid hydroperoxidation [45].
6. Conclusions
It has become clear over the years that lupus disease activity and severity can be modulated by
dietary intervention, as summarized in Table 1.
Table 1. Dietary components with possible impact on SLE.
Dietary
Component Model System Target Gene/Protein
Physiopathological
Process Effects Reference
n-3 PUFA SLE patients ↓ LTB4, IL-12, VLDL ↑ endothelialfunction, ↓ESR ↓ SLEDAI [7]
BW mice ↓ IL-6, IL-12, IL-18,TNF-α, IL-1β ↓ inflammation ↓ lupus nephritis [8,10]
↑ catalase, SOD, GPx ↑ anti-oxidantenzymes
MRL/lpr mice ↓ LTB4, IL-12, PGE2 ↓ inflammation ↓ disease [10]
Extra virgin
olive oil SLE patients’ PBMC
↓ IL-6, TNF-α, IL-1β,





↑ Tfh cells, DNA
hypomethylation ↑ inflammation [15]
MRL/lpr mice SGK1 ↑ Th1, Th17 cells ↓ lifespan. ↑ disease [14]
Vitamin A SLE patients ↓ inflammation ↓ proteinuria [19]





↓ lupus nephritis [21]
Vitamin D SLE patients MPO NETosis ↓ endothelial damage [18]
Phenylalanine,
Tyrosine BW mice mTOR
secondary to amino
acid metabolites
↓ lifespan. ↑ anti-DNA
Ab [22,23]
Methionine C57BL/6 × SJL mice LTB4, γ-GT,glutathione transmethylation
↓ anti-DNA Ab,
nephritis [33]
Ab, antibodies; ESR, erythrocyte sedimentation rate; GPx, glutathione peroxidase; γ-GT, γ-glutamil transaminase;
iNOS, inducible nitric oxide synthase; LTB4, leukotrien B4; MCP-1, monocyte chemoattractant protein-1; MPO,
myeloperoxidase; PGE2, prostaglandin E2; SGK1, glucocorticoid-inducible serine/threonine protein kinase 1; SLEDAI,
SLE disease activity index; SOD, superoxide dismutase; TET, ten eleven translocation; Tfh, T follicular helper; Tregs,
T regulatory cells; VLDL, very-low-density lipoproteins.
However, since there are more than 100 metabolites that are altered in lupus patients [32], dietary
targeting would need to be as comprehensive as possible and be combined with standard of care.
Moreover, a higher success rate may be expected when simultaneously targeting multiple factors or
pathways with a relevance in the disease pathogenesis.
Studies in rodents where dietary regimens can be tightly controlled have been informative
yet have at times resulted in pitfalls when attempting to extrapolate those results to SLE patients.
Notwithstanding these considerations, some dietary approaches that target a specific metabolic
pathway with a critical role in lupus pathogenesis, such as transmethylation, have shown promise
and are moving from preclinical work toward possible clinical use [33]. Further studies of selected
dietary modifications are poised to ultimately lead to improved lupus management, particularly when
derived from rigorous prospective and randomized trials [46].
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